Overview
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer
Description
This study is planned as a multicountry, non-interventional, longitudinal AI-enhanced digital registry that will leverage advanced data extraction technologies to efficiently generate RWD.
The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer.
Eligibility
Inclusion criteria:
Age ≥ 18 years at index date
- Diagnosis of mPC
- PSMA positive
- Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date
Exclusion criterion:
• Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)
